NYU Langone Health is a world-class academic medical center located in New York City, comprising NYU Grossman School of Medicine and multiple affiliated hospitals. Founded in 1941, NYU Langone has established itself as a global leader in neuroscience research and clinical care, with particular strengths in Alzheimer's disease, Parkinson's disease, Lewy body dementia, and other neurodegenerative disorders. The institution's strategic location in New York City provides access to one of the most diverse patient populations in the world, enabling research that addresses the full spectrum of neurodegenerative diseases across different ethnic and demographic groups.
[@neurology]
The institution houses the Alzheimer's Disease Research Center (ADRC), one of the NIH-funded Alzheimer's Disease Research Centers across the United States, as well as the Center for Brain Health, which focuses on cognitive enhancement and prevention strategies. The Institute for Neurology encompasses comprehensive programs in movement disorders, cognitive neurology, and neuroimaging, making NYU Langone one of the premier destinations for neurodegenerative disease research and patient care in the United States.
[@alzheimers]
NYU Langone Health traces its origins to the establishment of the NYU College of Medicine in 1941. Initially focused on training the next generation of physicians, the institution rapidly expanded its research capabilities, particularly in neuroscience and neurology. The establishment of dedicated neurology and neuroscience departments created the foundation for what would become one of the leading neurodegenerative disease research centers in the world.
The past two decades have seen remarkable growth in NYU Langone's neurodegenerative disease research programs. The establishment of the Alzheimer's Disease Research Center in 2016 brought significant NIH funding and enhanced the institution's capacity for cutting-edge research in Alzheimer's disease and related dementias. The Center for Brain Health, launched in 2019, represents a novel approach to neurodegenerative disease prevention, focusing on lifestyle interventions and cognitive enhancement strategies.
The institution has also invested heavily in advanced neuroimaging capabilities, establishing state-of-the-art MRI and PET facilities that enable visualization of amyloid and tau pathology in living patients. These capabilities have positioned NYU Langone at the forefront of early detection research, identifying individuals in the preclinical stages of Alzheimer's disease before significant cognitive decline occurs.
[@journal]
The NYU Langone Alzheimer's Disease Research Center (ADRC) is one of the premier Alzheimer's disease research centers in the United States, funded by the National Institute on Aging. The center brings together clinicians, basic scientists, and translational researchers to investigate all aspects of Alzheimer's disease pathogenesis, from molecular mechanisms to clinical intervention trials.
[@nature]
Early Detection and Prevention: The ADRC conducts comprehensive studies aimed at identifying individuals in the preclinical and prodromal stages of Alzheimer's disease. Through advanced biomarker testing and neuroimaging, researchers can detect amyloid and tau pathology years before the onset of clinical symptoms, enabling intervention strategies that may delay or prevent disease progression.
Biomarker Research: NYU Langone researchers have made significant contributions to the development and validation of Alzheimer's disease biomarkers. Key research areas include:
Clinical Trials: The ADRC coordinates numerous clinical trials testing novel therapeutic approaches for Alzheimer's disease, including:
The Center for Brain Health at NYU Langone represents an innovative approach to neurodegenerative disease prevention and cognitive enhancement. Unlike traditional research centers focused on disease treatment, the Center for Brain Health emphasizes prevention and optimization of brain function across the lifespan.
Cognitive Enhancement: Researchers investigate interventions that may enhance cognitive function in both healthy aging individuals and those with early cognitive impairment. Research areas include:
Lifestyle Interventions: The center conducts comprehensive studies on lifestyle factors that may protect against neurodegenerative diseases:
Brain Plasticity Research: Understanding the brain's capacity for adaptation and reorganization is a key focus of the Center for Brain Health. Research examines how the brain can compensate for neurodegeneration and maintain function through neuroplastic mechanisms.
The Institute for Neurology encompasses comprehensive programs in neurological disease research and clinical care. Key divisions include:
The Movement Disorders Division provides comprehensive care and conducts research on Parkinson's disease and related disorders:
The Cognitive Neurology Division focuses on diseases affecting cognition and behavior:
Advanced neuroimaging capabilities support both research and clinical care:
NYU Langone researchers have been pioneers in identifying individuals in the preclinical stages of Alzheimer's disease. Through longitudinal studies involving cognitive testing, biomarker analysis, and neuroimaging, researchers have characterized the temporal sequence of pathological changes leading to clinical dementia.
Key findings include:
NYU Langone has contributed significantly to biomarker development for Alzheimer's disease:
The institution has participated in numerous pivotal clinical trials for Alzheimer's disease:
NYU Langone is a major center for Parkinson's disease research and treatment:
Research extends beyond motor symptoms to address the full spectrum of Parkinson's disease manifestations:
NYU Langone researchers investigate potential disease-modifying therapies:
NYU Langone is a leading center for Lewy body dementia (LBD) research, investigating the relationship between alpha-synuclein aggregation and cognitive decline. Research programs address:
The institution's expertise in Lewy body dementia has attracted patients from around the world seeking evaluation and treatment for this challenging condition.
NYU Langone Health conducts numerous clinical trials for neurodegenerative diseases:
NYU Langone participates in multi-center observational studies:
The institution maintains well-characterized patient cohorts:
NYU Langone Health offers comprehensive training in neurodegenerative disease research and clinical care:
The institution provides training opportunities for:
NYU Langone hosts conferences and seminars on neurodegenerative diseases:
NYU Langone maintains extensive international collaborations:
NYU Langone participates in international research consortia:
NYU Langone provides access to state-of-the-art research infrastructure:
The institution maintains important research resources:
NYU Langone neurodegeneration research is supported by:
Active pharmaceutical partnerships support clinical development.
NYU Langone researchers have made significant contributions to:
The institution provides exceptional care for patients with neurodegenerative diseases, integrating research with clinical practice.
NYU Langone has trained numerous researchers and clinicians who now lead neurodegenerative disease programs worldwide.
Related pages in NeuroWiki:
Fluid Biomarkers:
[Biomarker validation in diverse populations^5